Condition

Renal Pelvic Carcinoma clinical trials and research

As of November 12, 2026, Find a Trial lists 3 Renal Pelvic Carcinoma clinical trials that are recruiting, in China. By phase: Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.

Newest Renal Pelvic Carcinoma clinical trials

StudyPhaseWhereStatusRegistered
Nephron-sparing tislelizumab and nab-paclitaxel for renal pelvic cancer Phase 2 Tianjin, Outside U.S. Recruiting Nov 18, 2025
Combining radiotherapy with systemic therapy for oligometastatic ureter cancer — Beijing and 1 other locations Recruiting Oct 22, 2024
Combining immunotherapy and radiotherapy after surgery for advanced ureter cancer — Beijing and 1 other locations Recruiting Sep 19, 2024

All recruiting trials (3)

Related topics

Ureter CancerAdvanced Urothelial CarcinomaNab-paclitaxelOligometastatic DiseasePD-1 InhibitorTislelizumabTislelizumab

Quick answers

How many Renal Pelvic Carcinoma clinical trials are recruiting right now?

3, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →

Last reviewed 2026-11-12 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.